Compare RPAY & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPAY | CVRX |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.5M | 237.1M |
| IPO Year | 2018 | 2021 |
| Metric | RPAY | CVRX |
|---|---|---|
| Price | $3.31 | $5.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $5.53 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 1.6M | 261.1K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $309,261,000.00 | $56,651,000.00 |
| Revenue This Year | $12.54 | $17.17 |
| Revenue Next Year | $4.66 | $17.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $2.30 | $4.37 |
| 52 Week High | $5.90 | $11.30 |
| Indicator | RPAY | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 30.92 |
| Support Level | $2.83 | $5.11 |
| Resistance Level | $3.87 | $8.25 |
| Average True Range (ATR) | 0.23 | 0.61 |
| MACD | -0.09 | -0.21 |
| Stochastic Oscillator | 9.24 | 13.06 |
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.